[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Sputnik V peer reviewed", "description": "Sputnik V (Gam-Covid-Vac)\n\n 2 doses, 3 weeks apart\n\nMuscle injection\n\nFreezer storage\n\nDeveloping an alternative formulation that can be refrigerated\n\nGamaleya Research Institute (Ministry of Health)\n\nCombination of two adenoviruses called Ad5 and Ad26\n\nAugust 11th President Putin announced approval\n\nBefore phase 3 trials had started\n\nNovember, Russian government began offering Sputnik V within Russia\n\nWidespread hesitancy\n\nPhase 3, Russia, Belarus, UAE, Venezuela, India\n\nGamaleya Institute joined forces in December with the AstraZeneca\n\nAstraZeneca / Gamaleya combination started Phase 1 trial on Dec. 24\n\n\nSafety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia \n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext\n\nBackground\n\nA heterologous recombinant adenovirus\n\nPhase 2 results,\n\nshowed a good safety profile and induced strong humoral and cellular immune responses\n\nInterim analysis of this phase 3 trial \nMethods\n\nRandomised, double-blind, placebo-controlled, phase 3 trial\n\n25 hospitals and polyclinics in Moscow\n\nParticipants at least 18 years, with negative PCR and IgG and IgM tests\n\nRandomly assigned (3:1) to receive vaccine or placebo\n\nTwo shots, 21 days apart\n\nFirst dose, rAd26\n\nSecond dose, rAd5),\n\nBoth vectors carrying the gene for the full-length SARS-CoV-2 glycoprotein S\n\nOutcome recorded 21 days after second shot (vaccine or placebo)\n\nFinding\n\nSept 7 to Nov 24, 2020\n\nN = 21 977\n\nRandomly assigned\n\nVaccine group, n = 16 501\n\nPlacebo group, n = 5476\n\nN = 19 866 received two doses of vaccine or placebo and were included\n\n(2,144 participants older than 60 years, 1,611 in the vaccine group and 533 in the placebo group)\n\nPrimary outcome analysis\n\nIncluded all participants who had received at least two doses at the time of database lock\n\nVaccine group, n = 14,964\n\n16 (0\u00b71%) confirmed COVID infections\n\nNo cases of moderate or severe COVID-19 confirmed at least 21 days after dose 1\n\nPlacebo group, n = 4,902\n\n62 (1\u00b73%) confirmed COVID infections\n\n20 cases of moderate or severe COVID-19 confirmed at least 21 days after dose 1\n\nEfficacy\n\n91\u00b76%\n\nVaccine efficacy was 91\u00b78 in participants older than 60 years\n\nInterim immunogenicity \n\nVaccine group\n\nRBD-specific IgG detected in 336 (98%) of 342 samples\n\nSeroconversion rate of 98\u00b725%\n\nHigher levels of interferon-gamma\n\n(secreted by activated T helper lymphocytes, T cytotoxic lymphocytes, B lymphocytes and NKs)\n\nSignificantly higher levels of IFN-\u03b3 secretion upon antigen restimulation\n\nPlacebo group\n\nRBD-specific IgG was detected in 17 (15%) of 114 samples\n\nSeroconversion rate of 14\u00b791%\n\n(p less than 0\u00b70001 vs the vaccine group)\n\nAdverse events\n\nGrade 1\n\n7485 [94\u00b70%] of 7966 total events\n\nSerous adverse events\n\nVaccine group\n\n\n45 (0\u00b73%) of 16, 427\n\nPlacebo group\n\n23 (0\u00b74%) of 5435\n\nNone were considered associated with vaccination\n\nFour deaths were reported during the study\n\nVaccine group\n\nThree (less than 0\u00b71%) of 16 427\n\nPlacebo group\n\nOne (less than 0\u00b71%) of 5435\n\nNone of which were considered related to the vaccine\n\nInterpretation\n\nThis interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91\u00b76% efficacy against COVID-19 and was well tolerated in a large cohort", "link": "https://www.youtube.com/watch?v=9_EQbDHQN88", "date_published": "2021-02-05 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vitamin D studies confirm correlations", "description": "Vitamin D\n\nUK biobank\n\nhttps://www.ukbiobank.ac.uk\n\nHabitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank (29th January, 2021)\n\nhttps://academic.oup.com/ajcn/advance-article/doi/10.1093/ajcn/nqaa381/6123965\n\nThe American Journal of Clinical Nutrition\n\nBackground \n\nVitamin D supplementation, lower risk of acute respiratory tract infection\n\nEmerging evidence, vitamin D insufficiency is related to a higher risk of coronavirus infection and disease\n\nObjectives\n\nTo investigate the prospective association between habitual use of vitamin D supplements and risk of COVID- 19 infection\n\nAssociations according to levels of circulating and genetically predicted vitamin D\n\nMethods\n\nN = 8,297 adults\n\nRecords of COVID-19 test results from UK Biobank\n\n16 March 2020 to 29 June 2020\n\nResults\n\nOf the 8,297 adults, 1,374 (16.6%) tested positive\n\nVit D users, n = 363\n\nNon-vit D users, n = 7,934\n\nUnadjusted model\n\nOR 0.78 (p = 0.105)\n\nAdjustment for covariates\n\nAge, sex, race, origin (outpatient or inpatient), blood-type, years of education, TDI, smoking, moderate drinking, physical activity, healthy diet score, use of any other supplements \n\nInverse association emerged\n\nBetween habitual use of vitamin D supplements and risk of COVID-19 infection\n\nOR, 0.66, (P = 0.038)\n\nHabitual use of vitamin D supplements was significantly associated with a 34% lower risk of COVID-19 infection\n\nNo association with baseline blood vitamin D levels and risk of COVID-19 infection\n\nAssociations between the risk of COVID-19 infection and habitual use of other individual supplements\n\nVitamin A, vitamin B, vitamin C, vitamin E, folic acid, a\nmultivitamin, \n\nCalcium, zinc, iron, selenium, glucosamine, fish\nOil\n\nVitamin D Deficiency and Outcome of COVID-19 Patients\n\nMedical University Hospital Heidelberg, (September 2020)\n\nhttps://www.mdpi.com/2072-6643/12/9/2757\n\nIdentification of modifiable prognostic factors may help to improve outcomes\n\nN = 185, diagnosed and treated in Heidelberg\n\nMedian Vitamin D level was 16.6 ng/ml\n\nAssociations of vitamin D status with disease severity and survival\n\nVitamin D status assessed at first presentation\n\nDeficient\n\n25-hydroxyvitamin D (Calcifediol)\nlevel less than 12 ng/mL ( less than 30 nM)\n\nN = 41 (22%)\n\nMedian IL-6 levels at hospitalization were significantly higher \n\n70.5 versus 29.7 pg/mL\n\nInsufficiency\n\nLess than 20 ng/mL (less than 50 nM) \n\nN = 118 (64%)\n\nHigher levels\n\nN = 26\n\nMedian Vitamin D level was significantly lower in the inpatient versus the outpatient subgroup\n\nResults\n\nMedian observation period of 66 days\n\n93 (50%) patients required hospitalization\n\n28 patients required ventilation\n\nIncluding 16 deaths\n\nAdjusting for age, sex, comorbidities\n\nDeficiency was associated with higher risk of ventilation and death\n\nMechanical ventilation\n\nHR 6.12\n\np less than 0.001\n\nDeath\n\nHR 14.73\n\np less than 0.001\n\nOther hazard ratios\n\nMale, 1.69 2.5\n\nOver 60, 3.2    7.7\n\nComorbidity, 2.7 5.3\n\nNeed for interventional studies\n\nCholecalciferol\n\nCalcifediol\n\nActive form of vitamin D3, 1, 25-dihydroxyvitamin D3 (1,25D3), calcitriol, is \npluripotent hormone and important modulator of both innate and adaptive immunity", "link": "https://www.youtube.com/watch?v=au6FKi8aAsA", "date_published": "2021-02-04 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]